Bifidobacterium bifidum PRS-179 and application and product thereof

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to bifidobacterium bifidum PRS-179 as well as application and a product thereof. The invention provides bifidobacterium bifidum, which is bifidobacterium bifidum PRS-179, and the preservation number of the bifidobacterium bifidum is CCTCC (China Center for Type Culture Collection) NO: M 20242016. The bifidobacterium bifidum PRS-179 can be proliferated by efficiently utilizing the 2 '-fucosyllactose, and the bifidobacterium bifidum PRS-179 has good tolerance to acid and bile. The invention provides a new thought for developing products helpful for regulating intestinal flora.

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to Bifidobacterium bifidum PRS-179 and its application and products. Background Art

[0002] 2'-Fucosyllactose (2'-FL) is a neutral fucosylated human milk oligosaccharide (HMOs), accounting for about 31% (molar fraction) of HMOs, with a content of 0.06-3.93g / L, and is the oligosaccharide with the highest relative abundance in human milk. The monomers of 2'-FL include fucose, galactose and glucose. It is precisely because of this unique structure that 2'-FL has special functions, making 2'-FL one of the HMOs that can be added to infant formula, ordinary food, dietary supplements and / or medical foods.

[0003] 2'-FL is a typical representative of neutral fucosylated HMOs. As a prebiotic, 2'-FL is a key nutrient source for infant intestinal microbial flora, especially for the growth and activity of beneficial bacteria in the intestine, promoting the growth and reproduction of beneficial bacteria, thereby inhibiting the growth of harmful bacteria, and helping infants to establish healthy intestinal flora. At the same time, it may also have a positive potential impact on infants' brain development and cognitive function, which is also indirectly achieved by regulating intestinal flora.

[0004] The development of probiotics that can effectively utilize 2'-FL and use it together with 2'-FL in products that help regulate intestinal flora is a current research hotspot. Probiotics can better colonize in the intestines after utilizing 2'-FL, which helps balance intestinal flora, enhance intestinal barrier function, and resist the invasion of harmful bacteria, thereby bringing positive effects to the human digestive and immune systems and ensuring the health of the human intestine. In the study of "The Effect of 2'-fucosyllactose on Probiotic Colonization and Anti-inflammatory Ability", Yang Wenjun et al. showed that 2'-FL can improve the colonization (adhesion, proliferation) ability and anti-inflammatory effect of lactic acid bacteria and bifidobacteria. However, the utilization effect of 2'-FL is strain-specific, and different strains have different utilization effects on 2'-FL. In addition, the premise for probiotics to colonize the intestine is that they can reach the intestine through a series of physical and chemical barriers, so potential probiotics should have good tolerance to acid and bile.

[0005] Therefore, developing a strain with good tolerance to the digestive tract environment and the ability to efficiently utilize 2'-FL can provide new ideas for developing products that help regulate intestinal flora. Summary of the invention

[0006] Based on the above-mentioned deficiencies, the present invention provides a Bifidobacterium bifidum PRS-179 and its application and product. The present invention provides a Bifidobacterium bifidum (Bifidobacterium bifidum), which is Bifidobacterium bifidum PRS-179, and the preservation number is CCTCC NO: M 20242016. The Bifidobacterium bifidum PRS-179 can efficiently utilize 2'-fucosyllactose for proliferation, and should have good tolerance to acid and bile. The present invention provides a new idea for the development of products that help regulate intestinal flora.

[0007] The technical solution of the present invention includes:

[0008] In a first aspect, the present invention provides a Bifidobacterium bifidum, wherein the Bifidobacterium bifidum is Bifidobacterium bifidum PRS-179, and the deposit number is CCTCC NO: M20242016.

[0009] Preferably, the 16S rDNA nucleotide sequence of Bifidobacterium bifidum PRS-179 is as shown in SEQ ID NO.1.

[0010] SEQ ID NO.1:

[0011]

[0012] In a second aspect, the present invention provides a Bifidobacterium bifidum preparation, which comprises one or more of the above-mentioned Bifidobacterium bifidum cells, fermentation broth, fermentation supernatant, fermentation broth precipitate, and freeze-dried powder.

[0013] In a third aspect, the present invention provides a method for culturing the above-mentioned Bifidobacterium bifidum, wherein the culturing method comprises inoculating Bifidobacterium bifidum PRS-179 into a culture medium for culturing.

[0014] Preferably, the culture medium includes, but is not limited to: MRS medium, TPY medium, MC medium or BCP medium.

[0015] Preferably, the culture medium can use 2'-fucosyllactose as the sole carbon source.

[0016] Preferably, the culture medium may use 2'-fucosyllactose together with other substances as carbon sources.

[0017] More preferably, the other substances include: one or more of carbohydrates, fats, organic acids, alcohols, and hydrocarbons.

[0018] In a fourth aspect, the present invention provides the use of the above-mentioned Bifidobacterium bifidum or Bifidobacterium bifidum preparation in the preparation of a product that helps to regulate intestinal flora.

[0019] Specifically, the products include but are not limited to food, health products or medicines.

[0020] In a fifth aspect, the present invention provides a food, comprising the above-mentioned Bifidobacterium bifidum or Bifidobacterium bifidum preparation.

[0021] Specifically, the food also includes nutrients that are acceptable in food science.

[0022] Preferably, the food-based acceptable nutrients include, but are not limited to, one or more of dietary fiber, protein, lipids, minerals, and vitamins.

[0023] Further preferably, the food-friendly nutrient comprises 2'-fucosyllactose.

[0024] Specifically, the dosage form of the food includes a liquid dosage form, a solid dosage form or a semi-solid dosage form.

[0025] Specifically, the food includes human food or animal food.

[0026] Preferably, the food includes candy, soy milk, yogurt, canned food, biscuits, chocolate, cakes, cream, cheese, milk powder, formula milk powder, ice cream, jam, puree, candied fruit, preserved fruit, bread, egg rolls, protein drinks, solid drinks, lactic acid bacteria drinks, plant protein drinks, carbonated drinks, coffee or puffed food.

[0027] In a sixth aspect, the present invention provides a health product, comprising the above-mentioned Bifidobacterium bifidum or Bifidobacterium bifidum preparation.

[0028] Specifically, the health care products also include nutritionally acceptable nutrients.

[0029] Preferably, the nutritionally acceptable nutrients include, but are not limited to, one or more of dietary fiber, protein, lipids, minerals, and vitamins.

[0030] Specifically, the dosage forms of the health care products include tablets, capsules, granules, pills, gel candies, powders, oral liquids or drops.

[0031] In a seventh aspect, the present invention provides a medicine, comprising the above-mentioned Bifidobacterium bifidum or Bifidobacterium bifidum preparation.

[0032] Specifically, the medicine also includes one or more pharmaceutically acceptable excipients.

[0033] Preferably, the pharmaceutically acceptable excipients include, but are not limited to, solvents, diluents, disintegrants, precipitation inhibitors, surfactants, glidants, adhesives, lubricants, dispersants, suspending agents, isotonic agents, thickeners, emulsifiers, preservatives, stabilizers, hydrating agents, emulsification accelerators, buffers, absorbents, colorants, flavoring agents, sweeteners, ion exchangers, release agents, coating agents, flavoring agents or antioxidants.

[0034] The beneficial effects of the present invention are:

[0035] The present invention provides a bifidobacterium bifidum, which is bifidobacterium bifidum PRS-179, and the deposit number is CCTCC NO: M 20242016. The bifidobacterium bifidum PRS-179 can efficiently utilize 2'-fucosyllactose for proliferation, and should have good tolerance to acid and bile. The present invention provides a new idea for developing products that help regulate intestinal flora.

[0036] Collection Instructions

[0037] Deposited strain: Bifidobacterium bifidum PRS-179;

[0038] Classification and nomenclature: Bifidobacterium bifidumPRS-179;

[0039] Deposit number: CCTCC NO:M 20242016;

[0040] Preservation time: September 20, 2024;

[0041] Depository: China Center for Type Culture Collection;

[0042] Deposit address: Wuhan University, Wuhan, China. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1 These are the morphological characteristics of Bifidobacterium bifidum PRS-179.

[0044] Figure 2 The Gram staining results of Bifidobacterium bifidum PRS-179.

[0045] Figure 3 This is the growth curve of Bifidobacterium bifidum PRS-179 in different culture systems.

[0046] Figure 4 2'-FL content of Bifidobacterium bifidum PRS-179 in different culture systems.

[0047] Figure 5 The growth curves of Bifidobacterium bifidum ATCC 15696 in different culture systems. DETAILED DESCRIPTION

[0048] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be clearly and completely described below. If the specific conditions are not specified in the embodiments, they are carried out according to the normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified in the reagents or instruments used, they are all conventional products that can be purchased commercially. The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0049] Example 1 Isolation, Identification and Preservation of Bifidobacterium bifidum

[0050] This example provides a strain of Bifidobacterium bifidum, and the isolation and identification process thereof is as follows:

[0051] 1. Isolation of Bifidobacterium bifidum

[0052] Healthy human feces were collected and diluted 10 times with PBS under sterile conditions. Three concentration gradients were selected and streaked on MRS agar medium (purchased from Qingdao Haibo Biotechnology Co., Ltd., item number: HB0384). Three replicates were made for each gradient. PBS was used as a blank control. The cells were placed in a 37°C constant temperature incubator for anaerobically cultured for 24-72 hours. Colonies of different morphologies were then selected for Gram staining and purification, and then streaked twice in MRS agar medium, and then stained for microscopic examination to observe the bacterial morphology and whether it was purified. The purified strain was named PRS-179.

[0053] 2. Identify strain PRS-179 as follows:

[0054] (1) Morphological characteristics of strain PRS-179 Figure 1 As shown, the colonies of strain PRS-179 are small, smooth, convex, with neat and complete edges, milky white in color, and a moist and smooth surface.

[0055] (2) Gram staining results of strain PRS-179 Figure 2 As shown, it is Gram-positive, does not form spores, and is short rod-shaped, sometimes with one end forked.

[0056] (3) The genome of the isolated PRS-179 was extracted and its 16S rDNA was sequenced and identified. The primer pairs used and their nucleotide sequences are as follows:

[0057] 27F: 5'-AGAGTTTGATCCTGGCTCAG-3' (SEQ ID NO. 2);

[0058] 1429R: 5'-TACGGYTACCTTGTTACGACTT-3' (SEQ ID NO. 3).

[0059] The above primers were used to amplify and sequence the 16S rDNA gene sequence of strain PRS-179, and the PCR amplification product was sent to Shanghai Sangon Biotechnology (Shanghai) Co., Ltd. for sequencing. The 16S rDNA nucleotide sequence of strain PRS-179 is shown in SEQID NO.1. After homology comparison of the 16S rDNA sequence through the NCBI library, it was found that the strain screened by the present invention had a similarity of 100.00% with the Bifidobacterium bifidum Bif24 strain. Combined with the physiological and biochemical identification results, strain PRS-179 was identified as a strain of Bifidobacterium bifidum, named Bifidobacterium bifidum PRS-179, and its physiological and biochemical properties are shown in Table 1 (Merieux kit API20A 20300).

[0060] Table 1 Physiological and biochemical identification results of strain PRS-179

[0061]

[0062]

[0063] Note: "+" in the table represents a positive result; "-" represents a negative result.

[0064] Furthermore, the whole genome was sequenced, and the extracted whole genome was sent to Suzhou Jinweizhi Biotechnology Co., Ltd. for second-generation sequencing. The obtained sequence results were compared with the reference strains in the NCBI database and identified as Bifidobacterium bifidum, with an ANI value of 99.99%.

[0065] 3. Preservation of strains

[0066] Bifidobacterium bifidum PRS-179 is deposited in the China Center for Type Microorganism Collection, with the deposit number being CCTCC NO:M 20242016 and the deposit date being September 20, 2024.

[0067] Example 2 Evaluation of digestive tract environmental tolerance characteristics

[0068] 1. Simulated Gastric Fluid (SGF) experiment

[0069] (1) Artificial gastric fluid: Take 2.0g NaCl and 3.2g pepsin (Solebo pepsin, 1:3000, labeled as 800-2500 activity units per mg), add 7.0mL 37% dilute hydrochloric acid and pure water to dissolve and dilute to 1000mL, the pH value of the solution is 1.2. Adjust the pH to 3.0 (simulating the pH of human intestinal fluid after meals and the pH of mouse fasting intestinal fluid), filter and sterilize;

[0070] (2) Collection of bacteria: Bifidobacterium bifidum PRS-179 was statically cultured at 37°C for 16-18 h until it reached the logarithmic growth phase. The bacterial solution was dispensed into 50 mL sterile EP tubes and centrifuged at 4000 rpm for 5 min at room temperature. The supernatant was discarded and the bacteria were resuspended in PBS. The OD600 value of the bacterial solution was adjusted to obtain a bacterial count of approximately 2 × 10 9 CFU / mL, then take a 15mL sterile EP tube, add 6mL of bacterial solution adjusted to OD value, centrifuge (same conditions as above), discard the supernatant, collect the bacterial mud for use, and keep 1 tube resuspended in PBS as the control group;

[0071] (3) Artificial gastric juice incubation: 6 mL of the above-mentioned artificial gastric juice with a pH of 3 was added to a 15 mL centrifuge tube containing bacterial sludge, and the mixture was mixed by pipetting. The viable bacteria were incubated for 3 h and then spread and counted. After 3 h of incubation, the number of viable bacteria remained at the same order of magnitude, indicating that the Bifidobacterium bifidum PRS-179 had a strong acid resistance;

[0072] (4) Calculation of gastric acid tolerance of bacteria: plate counting, recording the number of colonies on each plate, and data processing to obtain the gastric acid tolerance results of Bifidobacterium bifidum PRS-179 after being exposed to artificial gastric juice of different pH values ​​for different periods of time. The formula for calculating the survival rate is: survival rate = A2 / A1×100%; where: A1 is the number of viable bacteria (CFU / mL) after incubation in artificial gastric juice of different pH values ​​for 0 hours; A2 is the number of viable bacteria (CFU / mL) after incubation in artificial gastric juice of different pH values ​​for 3 hours.

[0073] 2. Experiment on simulating bile salt environment in human body

[0074] (1) Preparation of ox bile salt culture medium: Weigh 2 g / L (0.2%) ox bile salt (OXOID, LP0055) and add it to the target bacteria culture medium (MRS broth or other liquid culture medium), sterilize it by high pressure and set aside;

[0075] (2) Collection of bacteria: Bifidobacterium bifidum PRS-179 was statically cultured at 37°C for 16-18 h until it reached the logarithmic growth phase. The bacterial solution was dispensed into 50 mL sterile EP tubes and centrifuged at 4000 rpm for 5 min at room temperature. The supernatant was discarded and the bacteria were resuspended in PBS. The OD600 value of the bacterial solution was adjusted to obtain a bacterial count of approximately 2 × 10 9 CFU / mL, then take a 15mL sterile EP tube, add 6mL of bacterial solution adjusted to OD value, centrifuge (same conditions as above), discard the supernatant, collect the bacterial mud for use, and keep 1 tube resuspended in PBS as the control group;

[0076] (3) Incubation with ox bile salts: Add 3 ml of MRS broth containing 0.2% ox bile salts to the centrifuge tubes containing bacterial sludge and incubate for 3 h.

[0077] (4) Plate coating: dilute the incubated bacterial solution 10-fold, select three appropriate dilution multiples, evenly pipette 100uL of the dilution solution, and plate it. Set up three parallels for each concentration dilution solution and incubate at 37°C;

[0078] (5) Perform plate counting, record the number of colonies on each plate, and perform data processing to obtain the strain's bile salt tolerance. The survival rate is calculated as follows: survival rate = A2 / A1 × 100%: Where: A1 is the number of viable bacteria (CFU / mL) after incubation in 0.2% ox bile salt MRS broth for 0 hours; A2 is the number of viable bacteria (CFU / mL) after incubation for 3 hours.

[0079] The measurement results are shown in Table 2:

[0080] Table 2 Acid and bile resistance data of Bifidobacterium bifidum PRS-179

[0081] Test solution name Incubation time Viable bacteria count CFU / mL Live bacteria content% Artificial gastric juice pH = 3.0 3h <![CDATA[1.54×10 7 ]]> 54.04％ 0.2% ox bile salts MRS broth 3h <![CDATA[1.04×10 7 ]]> 36.50％

[0082] According to the above results, after incubation in artificial gastric juice with a pH of 3 for 3 hours, the survival rate of Bifidobacterium bifidum PRS-179 was calculated to be 54.04%, and the survival rate exceeded 50%, indicating that the bacteria had good acid resistance; after incubation for 3 hours at a concentration of 0.2% ox bile salt, the live bacteria rate still reached 36.50%, and the bacteria had good bile salt tolerance.

[0083] Example 3 Evaluation of the Utilization Characteristics of 2'-FL

[0084] This example conducts an experimental evaluation on the utilization characteristics of 2'-FL (2'-fucosyllactose) by Bifidobacterium bifidum PRS-179.

[0085] 1. Culture medium preparation

[0086] In the basic L-MRS medium, 2'-FL was used to replace the carbon source glucose. The concentration was consistent with glucose, which was 20g / L. Six different types of culture media were prepared and named A, B, C, D, E, and F. In terms of 1L, the formulas of each culture medium are:

[0087] A (without glucose): tryptone 10 g, beef extract 10 g, sodium acetate 2 g, yeast powder 5 g, MgSO4·7H2O 0.1 g, MnSO4·H2O 0.05 g, diammonium hydrogen citrate 2 g, K2HPO4 2 g, L-cysteine ​​1 g, Tween 80 1 mL;

[0088] B (A + glucose): tryptone 10 g, glucose 20 g, beef extract 10 g, sodium acetate 2 g, yeast powder 5 g, MgSO4·7H2O 0.1 g, MnSO4·H2O 0.05 g, diammonium hydrogen citrate 2 g, K2HPO4 2 g, L-cysteine ​​1 g, Tween 80 1 mL;

[0089] C(A+2'-FL): tryptone 10g, 2'-FL 20g, beef extract 10g, sodium acetate 2g, yeast powder 5g, MgSO4·7H2O 0.1g, MnSO4·H2O 0.05g, diammonium hydrogen citrate 2g, K2HPO4 2g, L-cysteine ​​1g, Tween 80 1mL;

[0090] D (without carbon and nitrogen sources): sodium acetate 2g, MgSO4·7H2O 0.1g, MnSO4·H2O 0.05g, diammonium hydrogen citrate 2g, K2HPO4 2g, L-cysteine ​​1g, Tween 80 1mL;

[0091] E(D+2'-FL): 2'-FL 20 g, sodium acetate 2 g, MgSO4·7H2O 0.1 g, MnSO4·H2O 0.05 g, diammonium hydrogen citrate 2 g, K2HPO4 2 g, L-cysteine ​​1 g, Tween 80 1 mL.

[0092] F (A+glucose+2'-FL): tryptone 10 g, glucose 20 g, 2'-FL 20 g, beef extract 10 g, sodium acetate 2 g, yeast powder 5 g, MgSO4·7H2O 0.1 g, MnSO4·H2O 0.05 g, diammonium hydrogen citrate 2 g, K2HPO4 2 g, L-cysteine ​​1 g, Tween 80 1 mL;

[0093] 2. Culture and testing

[0094] Bifidobacterium bifidum PRS-179 was subcultured and activated twice and then inoculated into 6 different culture media at a 5% inoculation rate in the logarithmic phase. Samples were taken every 2 hours and OD600 was measured with a UV spectrophotometer. The measurement was continued for 24 hours, and a growth curve was drawn with time as the horizontal axis and OD600 as the vertical axis.

[0095] The results of the test are as follows Figure 3 As shown in the figure, after replacing glucose with 2'-FL as the sole carbon source, the growth rate of Bifidobacterium bifidum PRS-179 slowed down compared with glucose, but the growth trend was better than that of the medium without carbon source. For the buffer system without carbon and nitrogen sources, only adding 2'-FL can significantly improve the growth ability of Bifidobacterium bifidum PRS-179, indicating that the strain can effectively utilize 2'-FL; after compounding 2'-FL and glucose, the growth rate of Bifidobacterium bifidum PRS-179 did not increase significantly, but the OD at the growth endpoint was improved, indicating that 2'-FL has a beneficial effect on the growth of this strain.

[0096] Furthermore, the 2'-FL content in the culture medium systems of groups C, E and F at the start and end points of the test was measured. The test results are as follows: Figure 4The test results showed that at 24 hours, only a small amount of 2'-FL remained in the culture medium of group E, indicating that the strain could effectively utilize 2'-FL in the absence of carbon and nitrogen sources; 2'-FL was almost consumed in the culture medium of groups C and F, and the remaining amount of 2'-FL in the culture medium of group F containing both glucose and 2'-FL was less than that in the culture medium of group C containing 2'-FL but not glucose, indicating that the strain could still effectively utilize 2'-FL when glucose was present, further indicating that Bifidobacterium bifidum PRS-179 could effectively utilize 2'-FL.

[0097] Comparative Example 1 Effect Evaluation of Bifidobacterium bifidum ATCC 15696

[0098] 1. Utilization characteristics of 2'-FL

[0099] The utilization characteristics of 2'-FL by Bifidobacterium bifidum ATCC 15696 were verified by referring to the method described in Example 3. Figure 5 As shown in the figure, after replacing glucose with 2'-FL as the sole carbon source, the growth rate of Bifidobacterium bifidum ATCC15696 slowed down compared with glucose, but the growth trend was better than that of the medium without glucose. For the buffer system without carbon and nitrogen sources, only adding 2'-FL can improve the growth ability of Bifidobacterium bifidum ATCC 15696, but the improvement effect is not obvious.

[0100] 2. Digestive tract environment tolerance

[0101] The digestive tract environmental tolerance characteristics of Bifidobacterium bifidum ATCC 15696 were evaluated by referring to the method described in Example 2. The test results are shown in Table 3:

[0102] Table 3 Digestive tract environmental tolerance characteristics of Bifidobacterium bifidum ATCC 15696

[0103]

[0104] According to the above results, it can be seen that Bifidobacterium bifidum ATCC 15696 is neither acid-resistant nor bile-resistant.

[0105] The above detailed description is a specific description of one of the feasible embodiments of the present invention, and the embodiment is not intended to limit the scope of the present invention. It should be pointed out that any equivalent implementation or change that does not deviate from the present invention should be included in the scope of the technical solution of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached requirements.

Claims

1. A Bifidobacterium bifidum, characterized in that The Bifidobacterium bifidum is Bifidobacterium bifidum PRS-179, and its preservation number is CCTCC NO: M 20242016.

2. A Bifidobacterium bifidum preparation, characterized in that The Bifidobacterium bifidum preparation comprises one or more of the cells, fermentation broth, fermentation supernatant, fermentation broth precipitate and freeze-dried powder of the Bifidobacterium bifidum according to claim 1.

3. The method for culturing Bifidobacterium bifidum according to claim 1, characterized in that: The culture method comprises inoculating Bifidobacterium bifidum PRS-179 into a culture medium for culture.

4. The culture method according to claim 3, characterized in that The culture medium includes: MRS culture medium, TPY culture medium, MC culture medium or BCP culture medium.

5. The culture method according to claim 3, characterized in that: The culture medium may use 2'-fucosyllactose as the sole carbon source.

6. The culture method according to claim 3, characterized in that: The culture medium can use 2'-fucosyllactose and other substances as carbon sources; the other substances include: one or more of carbohydrates, fats, organic acids, alcohols, and hydrocarbons.

7. Use of the Bifidobacterium bifidum according to claim 1 or the Bifidobacterium bifidum preparation according to claim 2 in the preparation of a product that helps regulate intestinal flora.

8. The use according to claim 7, characterized in that: The products include food, health products or medicines.

9. A food, characterized in that The food comprises the Bifidobacterium bifidum according to claim 1 or the Bifidobacterium bifidum preparation according to claim 2.

10. The food according to claim 9, characterized in that The food also includes nutrient substances that are acceptable in food science.

11. The food according to claim 10, characterized in that The food-based acceptable nutrients include one or more of dietary fiber, protein, lipids, minerals, and vitamins.

12. The food according to claim 9, characterized in that The dosage form of the food includes liquid dosage form, solid dosage form or semi-solid dosage form.

13. The food according to claim 9, characterized in that The food includes human food or animal food.

14. A health product, characterized in that: The health product comprises the Bifidobacterium bifidum according to claim 1 or the Bifidobacterium bifidum preparation according to claim 2.

15. The health product according to claim 14, characterized in that: The health care products also include nutritionally acceptable nutrients.

16. The health product according to claim 14, characterized in that: The dosage forms of the health care products include tablets, capsules, granules, pills, gel candies, powders, oral liquids or drops.

17. A medicine, characterized in that: The medicine comprises the Bifidobacterium bifidum according to claim 1 or the Bifidobacterium bifidum preparation according to claim 2.

18. The drug according to claim 17, characterized in that The medicine also includes one or more pharmaceutically acceptable excipients.

Images